Gregor K Wenning

List of Publications by Year in Descending Order

245 papers	14,412 citations	60 h-index	116 g-index
280 ext. papers	17,149 ext. citations	6.8 avg, IF	6.38 L-index

#	Paper	IF	Citations
245	Cardiac sympathetic innervation in Parkinson's disease versus multiple system atrophy.. *Clinical Autonomic Research*, **2022**, 1	4.3	0
244	Multiple System Atrophy (MSA) **2022**, 2409-2432		
243	The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy.. *Movement Disorders*, **2022**,	7	19
242	Instrumented gait analysis defines the walking signature of CACNA1A disorders. *Journal of Neurology*, **2021**, 1	5.5	2
241	The role of cardiovascular autonomic failure in the differential diagnosis of synucleinopathies. *Neurological Sciences*, **2021**, 43, 187	3.5	0
240	Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [C]PBR28 and Machine Learning Analysis. *Movement Disorders*, **2021**,	7	3
239	Characterization of gait variability in multiple system atrophy and Parkinson's disease. *Journal of Neurology*, **2021**, 268, 1770-1779	5.5	3
238	Recommendations for tilt table testing and other provocative cardiovascular autonomic tests in conditions that may cause transient loss of consciousness : Consensus statement of the European Federation of Autonomic Societies (EFAS) endorsed by the American Autonomic Society (AAS) and the European Academy of Neurology (EAN). *Clinical Autonomic Research*, **2021**, 31, 369-384	4.3	7
237	Emergent creativity in frontotemporal dementia. *Journal of Neural Transmission*, **2021**, 128, 279-293	4.3	4
236	Laboratory-Supported Multiple System Atrophy beyond Autonomic Function Testing and Imaging: A Systematic Review by the MoDiMSA Study Group. *Movement Disorders Clinical Practice*, **2021**, 8, 322-340	2.2	3
235	Characterization and diagnostic potential of diffusion tractography in multiple system atrophy. *Parkinsonism and Related Disorders*, **2021**, 85, 30-36	3.6	2
234	Dysphagia in multiple system atrophy consensus statement on diagnosis, prognosis and treatment. *Parkinsonism and Related Disorders*, **2021**, 86, 124-132	3.6	5
233	Neuropathology of multiple system atrophy: Kurt Jellinger's legacy. *Journal of Neural Transmission*, **2021**, 128, 1481-1494	4.3	1
232	Diagnostic accuracy of MR planimetry in clinically unclassifiable parkinsonism. *Parkinsonism and Related Disorders*, **2021**, 82, 87-91	3.6	5
231	Shared Genetics of Multiple System Atrophy and Inflammatory Bowel Disease. *Movement Disorders*, **2021**, 36, 449-459	7	2
230	Automated Analysis of Diffusion-Weighted Magnetic Resonance Imaging for the Differential Diagnosis of Multiple System Atrophy from Parkinson's Disease. *Movement Disorders*, **2021**, 36, 241-245	7	3
229	Cardiovascular autonomic failure in Parkinson's disease. *International Review of Movement Disorders*, **2021**, 1, 119-146		

228	Electrodiagnostic assessment of the autonomic nervous system: A consensus statement endorsed by the American Autonomic Society, American Academy of Neurology, and the International Federation of Clinical Neurophysiology. *Clinical Neurophysiology*, **2021**, 132, 666-682	4.3	20
227	Limitations of the Unified Multiple System Atrophy Rating Scale as outcome measure for clinical trials and a roadmap for improvement. *Clinical Autonomic Research*, **2021**, 31, 157-164	4.3	5
226	ATH434 Reduces □Synuclein-Related Neurodegeneration in a Murine Model of Multiple System Atrophy. *Movement Disorders*, **2021**, 36, 2605-2614	7	2
225	Urodynamic Evaluation in Multiple System Atrophy: A Retrospective Cohort Study. *Movement Disorders Clinical Practice*, **2021**, 8, 1052-1060	2.2	3
224	Recommendations for tilt table testing and other provocative cardiovascular autonomic tests in conditions that may cause transient loss of consciousness : Consensus statement of the European Federation of Autonomic Societies (EFAS) endorsed by the American Autonomic Society (AAS) and the European Academy of Neurology (EAN). *Autonomic Neuroscience: Basic and Clinical*, **2021**, 233, 102792	2.4	11
223	Orthostatic Hypotension in Parkinson□s Disease: Do Height and Weight Matter?. *Movement Disorders*, **2021**, 36, 2703-2705	7	1
222	Current experimental disease-modifying therapeutics for multiple system atrophy. *Journal of Neural Transmission*, **2021**, 128, 1529-1543	4.3	2
221	Is Multiple System Atrophy a Prion-like Disorder?. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	3
220	Female sexual dysfunction in multiple system atrophy: a prospective cohort study. *Clinical Autonomic Research*, **2021**, 31, 713-717	4.3	1
219	Toll-like receptor 4 deficiency facilitates □synuclein propagation and neurodegeneration in a mouse model of prodromal Parkinson□s disease. *Parkinsonism and Related Disorders*, **2021**, 91, 59-65	3.6	2
218	Autonomic failure: a neglected presentation of Parkinson□s disease. *Lancet Neurology, The*, **2021**, 20, 781-782	24.1	1
217	Reliability and validity of Japanese version of Unified Multiple System Atrophy Rating Scale. *Neurology and Clinical Neuroscience*, **2021**, 9, 171-180	0.3	0
216	Conjugal multiple system atrophy: Rethinking numbers of probability. *Parkinsonism and Related Disorders*, **2020**, 77, 176-177	3.6	1
215	Cardiovascular autonomic function testing in multiple system atrophy and Parkinson□s disease: an expert-based blinded evaluation. *Clinical Autonomic Research*, **2020**, 30, 255-263	4.3	8
214	Which Autonomic Features Distinguish Multiple System Atrophy and When. *Movement Disorders*, **2020**, 35, 902-903	7	
213	Effects of self-administered cannabidiol in a patient with multiple system atrophy. *Clinical Autonomic Research*, **2020**, 30, 355-356	4.3	2
212	Validation of the Neurogenic Orthostatic Hypotension Ratio with Active Standing. *Annals of Neurology*, **2020**, 88, 643-645	9.4	9
211	The footprint of orthostatic hypotension in parkinsonian syndromes. *Parkinsonism and Related Disorders*, **2020**, 77, 107-109	3.6	1

210	Novel decision algorithm to discriminate parkinsonism with combined blood and imaging biomarkers. *Parkinsonism and Related Disorders*, **2020**, 77, 57-63	3.6	9
209	Cognition in multiple system atrophy: a single-center cohort study. *Annals of Clinical and Translational Neurology*, **2020**, 7, 219-228	5.3	12
208	High-salt diet does not boost neuroinflammation and neurodegeneration in a model of □synucleinopathy. *Journal of Neuroinflammation*, **2020**, 17, 35	10.1	6
207	Olfaction in patients with isolated REM sleep behavior disorder who eventually develop multiple system atrophy. *Sleep*, **2020**, 43,	1.1	5
206	Cardiovascular autonomic testing in the work-up of cerebellar ataxia: insight from an observational single center study. *Journal of Neurology*, **2020**, 267, 1097-1102	5.5	3
205	Management of Orthostatic Hypotension in Parkinson□s Disease. *Journal of Parkinsonls Disease*, **2020**, 10, S57-S64	5.3	10
204	Non-Motor Symptoms in Parkinson□s Disease are Reduced by Nabilone. *Annals of Neurology*, **2020**, 88, 712-722	9.4	23
203	Association of transient orthostatic hypotension with falls and syncope in patients with Parkinson disease. *Neurology*, **2020**, 95, e2854-e2865	6.5	8
202	Commentary: Discriminating □synuclein strains in parkinson□s disease and multiple system atrophy. *Frontiers in Neuroscience*, **2020**, 14, 802	5.1	1
201	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the Movement Disorder Society Multiple System Atrophy Study Group. *Movement Disorders Clinical Practice*, **2020**, 7, 750-762	2.2	13
200	Signs of Chronic Hypoxia Suggest a Novel Pathophysiological Event in □Synucleinopathies. *Movement Disorders*, **2020**, 35, 2333-2338	7	5
199	Gait and postural disorders in parkinsonism: a clinical approach. *Journal of Neurology*, **2020**, 267, 3169-3176	5.5	9
198	Gender differences in clinical, laboratory and polysomnographic features of restless legs syndrome. *Journal of Sleep Research*, **2020**, 29, e12875	5.8	8
197	Parkinsonism and dysautonomia: Multiple system atrophy?. *Parkinsonism and Related Disorders*, **2020**, 77, 150-151	3.6	
196	Diagnostic Potential of Multimodal MRI Markers in Atypical Parkinsonian Disorders. *Journal of Parkinsonls Disease*, **2019**, 9, 681-691	5.3	10
195	Stridor in multiple system atrophy: Consensus statement on diagnosis, prognosis, and treatment. *Neurology*, **2019**, 93, 630-639	6.5	38
194	The Diagnostic Scope of Sensor-Based Gait Analysis in Atypical Parkinsonism: Further Observations. *Frontiers in Neurology*, **2019**, 10, 5	4.1	13
193	Induced pluripotent stem cells in multiple system atrophy: recent developments and scientific challenges. *Clinical Autonomic Research*, **2019**, 29, 385-395	4.3	2

192	A critique of the second consensus criteria for multiple system atrophy. *Movement Disorders*, **2019**, 34, 975-984	7	44
191	TNF-inhibitors as targets for protective therapies in MSA: a viewpoint. *Journal of Neuroinflammation*, **2019**, 16, 80	10.1	4
190	Iron in Neurodegeneration - Cause or Consequence?. *Frontiers in Neuroscience*, **2019**, 13, 180	5.1	101
189	Morphometric MRI profiles of multiple system atrophy variants and implications for differential diagnosis. *Movement Disorders*, **2019**, 34, 1041-1048	7	16
188	Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. *Alzheimerls and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2019**, 11, 301-309	5.2	14
187	Which way does the axis tip? IBD increases the risk of Parkinsons disease. *Gut*, **2019**, 68, 3	19.2	1
186	Abnormalities on structural MRI associate with faster disease progression in multiple system atrophy. *Parkinsonism and Related Disorders*, **2019**, 58, 23-27	3.6	12
185	The molecular tweezer CLR01 reduces aggregated, pathologic, and seeding-competent -synuclein in experimental multiple system atrophy. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2019**, 1865, 165513	6.9	15
184	Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial. *Lancet Neurology, The*, **2019**, 18, 724-735	24.1	42
183	Urinary retention discriminates multiple system atrophy from Parkinsons disease. *Movement Disorders*, **2019**, 34, 1926-1928	7	9
182	Physiotherapy improves motor function in patients with the Parkinson variant of multiple system atrophy: A prospective trial. *Parkinsonism and Related Disorders*, **2019**, 67, 60-65	3.6	13
181	Early distinction of Parkinson-variant multiple system atrophy from Parkinsons disease. *Movement Disorders*, **2019**, 34, 440-441	7	17
180	Multiple system atrophy. *International Review of Neurobiology*, **2019**, 149, 137-192	4.4	35
179	Management of supine hypertension in patients with neurogenic orthostatic hypotension: scientific statement of the American Autonomic Society, European Federation of Autonomic Societies, and the European Society of Hypertension. *Journal of Hypertension*, **2019**, 37, 1541-1546	1.9	33
178	SYNE1-ataxia: Novel genotypic and phenotypic findings. *Parkinsonism and Related Disorders*, **2019**, 62, 210-214	3.6	6
177	Anle138b modulates -synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy. *Movement Disorders*, **2019**, 34, 255-263	7	40
176	The diagnostic accuracy of the hummingbird and morning glory sign in patients with neurodegenerative parkinsonism. *Parkinsonism and Related Disorders*, **2018**, 54, 90-94	3.6	29
175	The Relevance of Iron in the Pathogenesis of Multiple System Atrophy: A Viewpoint. *Journal of Alzheimerls Disease*, **2018**, 61, 1253-1273	4.3	24

174	The reorganization of functional architecture in the early-stages of Parkinson's disease. *Parkinsonism and Related Disorders*, **2018**, 50, 61-68	3.6	42
173	Diagnostic potential of dentatorubrothalamic tract analysis in progressive supranuclear palsy. *Parkinsonism and Related Disorders*, **2018**, 49, 81-87	3.6	17
172	Autonomic function testing in spinocerebellar ataxia type 2. *Clinical Autonomic Research*, **2018**, 28, 341-346	4.9	9
171	Progressive striatonigral degeneration in a transgenic mouse model of multiple system atrophy: translational implications for interventional therapies. *Acta Neuropathologica Communications*, **2018**, 6, 2	7.3	34
170	Screening for idiopathic REM sleep behavior disorder: usefulness of actigraphy. *Sleep*, **2018**, 41,	1.1	21
169	Multiple system atrophy: experimental models and reality. *Acta Neuropathologica*, **2018**, 135, 33-47	14.3	14
168	Limited effects of dysfunctional macroautophagy on the accumulation of extracellularly derived synuclein in oligodendroglia: implications for MSA pathogenesis. *BMC Neuroscience*, **2018**, 19, 32	3.2	7
167	Sensor-based gait analysis in atypical parkinsonian disorders. *Brain and Behavior*, **2018**, 8, e00977	3.4	28
166	Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study. *Parkinsonism and Related Disorders*, **2018**, 56, 33-40	3.6	14
165	Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. *Neurology*, **2018**, 90, 74-82	6.5	10
164	MR planimetry in neurodegenerative parkinsonism yields high diagnostic accuracy for PSP. *Parkinsonism and Related Disorders*, **2018**, 46, 47-55	3.6	33
163	Region-Specific Effects of Immunotherapy With Antibodies Targeting synuclein in a Transgenic Model of Synucleinopathy. *Frontiers in Neuroscience*, **2018**, 12, 452	5.1	18
162	Consensus statement on the definition of neurogenic supine hypertension in cardiovascular autonomic failure by the American Autonomic Society (AAS) and the European Federation of Autonomic Societies (EFAS) : Endorsed by the European Academy of Neurology (EAN) and the European Society of Hypertension (ESH). *Clinical Autonomic Research*, **2018**, 28, 355-362	4.3	102
161	Autonomic function testing in Friedreich's ataxia. *Journal of Neurology*, **2018**, 265, 2015-2022	5.5	10
160	Very late-onset pure autonomic failure. *Movement Disorders*, **2017**, 32, 1106-1108	7	3
159	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. *Movement Disorders*, **2017**, 32, 853-864	7	840
158	Multiple system atrophy: insights into a rare and debilitating movement disorder. *Nature Reviews Neurology*, **2017**, 13, 232-243	15	96
157	Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms. *Journal of Neural Transmission*, **2017**, 124, 1567-1605	4.3	46

156	Diffusion-weighted MRI distinguishes Parkinson disease from the parkinsonian variant of multiple system atrophy: A systematic review and meta-analysis. *PLoS ONE*, **2017**, 12, e0189897	3.7	26
155	Toll-like receptor 4 stimulation with monophosphoryl lipid A ameliorates motor deficits and nigral neurodegeneration triggered by extraneuronal α-synucleinopathy. *Molecular Neurodegeneration*, **2017**, 12, 52	19	54
154	Cognitive impairment in multiple system atrophy. *Movement Disorders*, **2017**, 32, 1338-1339	7	15
153	Critical appraisal of clinical trials in multiple system atrophy: Toward better quality. *Movement Disorders*, **2017**, 32, 1356-1364	7	8
152	Brain structural profile of multiple system atrophy patients with cognitive impairment. *Journal of Neural Transmission*, **2017**, 124, 293-302	4.3	36
151	Autonomic History Taking and Key Symptoms: Where Is the Autonomic Disease? **2017**, 15-36		1
150	Glia and alpha-synuclein in neurodegeneration: A complex interaction. *Neurobiology of Disease*, **2016**, 85, 262-274	7.5	128
149	Overlaps between multiple system atrophy and multiple sclerosis: A novel perspective. *Movement Disorders*, **2016**, 31, 1767-1771	7	5
148	Is Multiple System Atrophy a New Prion Disorder?. *Movement Disorders*, **2016**, 31, 300	7	1
147	Neuroprotection by Epigenetic Modulation in a Transgenic Model of Multiple System Atrophy. *Neurotherapeutics*, **2016**, 13, 871-879	6.4	13
146	The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach. *Journal of Neural Transmission*, **2016**, 123, 439-45	4.3	21
145	Supine hypertension in Parkinson's disease and multiple system atrophy. *Clinical Autonomic Research*, **2016**, 26, 97-105	4.3	62
144	Evidenzbasierte Therapie der neurogenen orthostatischen Hypotonie. *InFo Neurologie & Psychiatrie*, **2016**, 18, 36-43	0	
143	Distinct Parameters in the EEG of the PLP-SYN Mouse Model for Multiple System Atrophy Reinforce Face Validity. *Frontiers in Behavioral Neuroscience*, **2016**, 10, 252	3.5	12
142	Anle138b Partly Ameliorates Motor Deficits Despite Failure of Neuroprotection in a Model of Advanced Multiple System Atrophy. *Frontiers in Neuroscience*, **2016**, 10, 99	5.1	16
141	Changes in the miRNA-mRNA Regulatory Network Precede Motor Symptoms in a Mouse Model of Multiple System Atrophy: Clinical Implications. *PLoS ONE*, **2016**, 11, e0150705	3.7	20
140	Preface. *Movement Disorders*, **2016**, 31, 151	7	
139	Toward disease modification in multiple system atrophy: Pitfalls, bottlenecks, and possible remedies. *Movement Disorders*, **2016**, 31, 235-40	7	7

138	Minimally clinically important decline in the parkinsonian variant of multiple system atrophy. *Movement Disorders*, **2016**, 31, 1577-1581	7	6
137	Diagnostic potential of automated subcortical volume segmentation in atypical parkinsonism. *Neurology*, **2016**, 86, 1242-9	6.5	60
136	Multiple system atrophy: pathogenic mechanisms and biomarkers. *Journal of Neural Transmission*, **2016**, 123, 555-72	4.3	43
135	Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. *Lancet Neurology, The*, **2015**, 14, 145-52	24.1	69
134	Animal models of multiple system atrophy. *Clinical Autonomic Research*, **2015**, 25, 9-17	4.3	26
133	Multiple system atrophy in the USA: another piece in the jigsaw. *Lancet Neurology, The*, **2015**, 14, 672-4	24.1	
132	Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. *Nature Communications*, **2015**, 6, 7247	17.4	118
131	Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative. *Neurobiology of Disease*, **2015**, 80, 29-41	7.5	48
130	Enteric nervous system □synuclein immunoreactivity in idiopathic REM sleep behavior disorder. *Neurology*, **2015**, 85, 1761-8	6.5	94
129	Sex and age effects on cardiovascular autonomic function in healthy adults. *Clinical Autonomic Research*, **2015**, 25, 317-26	4.3	16
128	Failure of Neuroprotection Despite Microglial Suppression by Delayed-Start Myeloperoxidase Inhibition in a Model of Advanced Multiple System Atrophy: Clinical Implications. *Neurotoxicity Research*, **2015**, 28, 185-94	4.3	23
127	Cerebral autoregulation and white matter lesions in Parkinson□s disease and multiple system atrophy. *Parkinsonism and Related Disorders*, **2015**, 21, 1393-7	3.6	22
126	Animal Models of Multiple-System Atrophy **2015**, 887-904		
125	Overexpression of □synuclein in oligodendrocytes does not increase susceptibility to focal striatal excitotoxicity. *BMC Neuroscience*, **2015**, 16, 86	3.2	4
124	Dorsolateral nigral hyperintensity on 3.0T susceptibility-weighted imaging in neurodegenerative Parkinsonism. *Movement Disorders*, **2015**, 30, 1068-76	7	96
123	Involvement of Peripheral Nerves in the Transgenic PLP-□Syn Model of Multiple System Atrophy: Extending the Phenotype. *PLoS ONE*, **2015**, 10, e0136575	3.7	13
122	Multiple-system atrophy. *New England Journal of Medicine*, **2015**, 372, 1375-6	59.2	46
121	Multiple-system atrophy. *New England Journal of Medicine*, **2015**, 372, 249-63	59.2	401

120	Models of multiple system atrophy. *Current Topics in Behavioral Neurosciences*, **2015**, 22, 369-93	3.4	13
119	Rifampicin for multiple system atrophy. *Lancet Neurology, The*, **2014**, 13, 237-9	24.1	3
118	Cognitive impairment in multiple system atrophy: a position statement by the Neuropsychology Task Force of the MDS Multiple System Atrophy (MODIMSA) study group. *Movement Disorders*, **2014**, 29, 857-67	7	148
117	Detecting nocturnal hypertension in Parkinson's disease and multiple system atrophy: proposal of a decision-support algorithm. *Journal of Neurology*, **2014**, 261, 1291-9	5.5	36
116	Autonomic failure in CANVAS syndrome. *Brain*, **2014**, 137, 2625-6	11.2	2
115	Multiple system atrophy as emerging template for accelerated drug discovery in α-synucleinopathies. *Parkinsonism and Related Disorders*, **2014**, 20, 793-9	3.6	18
114	Do periodic arm movements during sleep exist in healthy subjects? A polysomnographic study. *Sleep Medicine*, **2014**, 15, 1150-4	4.6	6
113	Cognition in a multiple system atrophy series of cases from Argentina. *Arquivos De Neuro-Psiquiatria*, **2014**, 72, 773-6	1.6	5
112	An update on the cerebellar subtype of multiple system atrophy. *Cerebellum and Ataxias*, **2014**, 1, 14	1.7	13
111	Towards translational therapies for multiple system atrophy. *Progress in Neurobiology*, **2014**, 118, 19-35	10.9	33
110	Clinical Presentation **2014**, 97-119		
109	Clinical Diagnostic Criteria **2014**, 121-132		
108	Neurogenic orthostatic hypotension: pathophysiology, evaluation, and management. *Journal of Neurology*, **2013**, 260, 2212-9	5.5	77
107	Multiple system atrophy. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2013**, 117, 229-41	3	21
106	The natural history of multiple system atrophy: a prospective European cohort study. *Lancet Neurology, The*, **2013**, 12, 264-74	24.1	322
105	Multiple System Atrophy (MSA) **2013**, 2119-2141		
104	Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia. *Glia*, **2013**, 61, 349-60	9	422
103	Oligodendroglial alpha-synucleinopathy and MSA-like cardiovascular autonomic failure: experimental evidence. *Experimental Neurology*, **2013**, 247, 531-6	5.7	43

102	Bladder dysfunction in a transgenic mouse model of multiple system atrophy. *Movement Disorders*, **2013**, 28, 347-55	7	44
101	Intact olfaction in a mouse model of multiple system atrophy. *PLoS ONE*, **2013**, 8, e64625	3.7	18
100	Premotor signs and symptoms of multiple system atrophy. *Lancet Neurology, The*, **2012**, 11, 361-8	24.1	108
99	Myeloperoxidase inhibition ameliorates multiple system atrophy-like degeneration in a transgenic mouse model. *Neurotoxicity Research*, **2012**, 21, 393-404	4.3	75
98	The Unified Multiple System Atrophy Rating Scale: intrarater reliability. *Movement Disorders*, **2012**, 27, 1683-5	7	12
97	An antibody microarray analysis of serum cytokines in neurodegenerative Parkinsonian syndromes. *Proteome Science*, **2012**, 10, 71	2.6	18
96	Behavioral and histological analysis of a partial double-lesion model of parkinson-variant multiple system atrophy. *Journal of Neuroscience Research*, **2012**, 90, 1284-95	4.4	9
95	Progression of dopamine transporter decline in patients with the Parkinson variant of multiple system atrophy: a voxel-based analysis of [123I]ßCIT SPECT. *European Journal of Nuclear Medicine and Molecular Imaging*, **2012**, 39, 1012-20	8.8	35
94	Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human ß-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. *Acta Neuropathologica*, **2012**, 124, 51-65	14.3	64
93	Toll-like receptor 4 promotes ß-synuclein clearance and survival of nigral dopaminergic neurons. *American Journal of Pathology*, **2011**, 179, 954-63	5.8	189
92	Genetic players in multiple system atrophy: unfolding the nature of the beast. *Neurobiology of Aging*, **2011**, 32, 1924.e5-14	5.6	33
91	New insights into atypical parkinsonism. *Current Opinion in Neurology*, **2011**, 24, 331-8	7.1	25
90	Excessive daytime sleepiness in multiple system atrophy (SLEEMSA study). *Archives of Neurology*, **2011**, 68, 223-30		73
89	Glial dysfunction in the pathogenesis of ß-synucleinopathies: emerging concepts. *Acta Neuropathologica*, **2011**, 121, 675-93	14.3	149
88	Modelling progressive autonomic failure in MSA: where are we now?. *Journal of Neural Transmission* , **2011**, 118, 841-7	4.3	2
87	A novel computer-assisted image analysis of [123I]ßCIT SPECT images improves the diagnostic accuracy of parkinsonian disorders. *European Journal of Nuclear Medicine and Molecular Imaging*, **2011**, 38, 702-10	8.8	25
86	Erythropoietin is neuroprotective in a transgenic mouse model of multiple system atrophy. *Movement Disorders*, **2011**, 26, 507-515	7	14
85	Milestones in atypical and secondary Parkinsonisms. *Movement Disorders*, **2011**, 26, 1083-95	7	58

84	Mesenchymal stem cells in a transgenic mouse model of multiple system atrophy: immunomodulation and neuroprotection. *PLoS ONE*, **2011**, 6, e19808	3.7	69
83	Combination Lesion Models of MSA. *Neuromethods*, **2011**, 37-54	0.4	
82	Etiology, Pathology, and Pathogenesis. *Blue Books of Neurology*, **2010**, 34, 321-339		2
81	Multiple system atrophy masking multiple sclerosis. *Clinical Neurology and Neurosurgery*, **2010**, 112, 59-61	1	5
80	Targeted overexpression of human alpha-synuclein in oligodendroglia induces lesions linked to MSA-like progressive autonomic failure. *Experimental Neurology*, **2010**, 224, 459-64	5.7	59
79	Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). *Movement Disorders*, **2010**, 25, 97-107	7	136
78	Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. *Movement Disorders*, **2010**, 25, 2604-12	7	155
77	SNCA variants are associated with increased risk for multiple system atrophy. *Annals of Neurology*, **2009**, 65, 610-4	9.4	232
76	Striatal transplantation in a rodent model of multiple system atrophy: effects on L-Dopa response. *Journal of Neuroscience Research*, **2009**, 87, 1679-85	4.4	23
75	Mitochondrial inhibitor 3-nitroproprionic acid enhances oxidative modification of alpha-synuclein in a transgenic mouse model of multiple system atrophy. *Journal of Neuroscience Research*, **2009**, 87, 2728-39	4.4	71
74	Assessing disease progression with MRI in atypical parkinsonian disorders. *Movement Disorders*, **2009**, 24 Suppl 2, S699-702	7	17
73	Clinically probable multiple system atrophy with predominant parkinsonism associated with myotonic dystrophy type 2. *Movement Disorders*, **2009**, 24, 1407-9	7	8
72	A validation exercise on the new consensus criteria for multiple system atrophy. *Movement Disorders*, **2009**, 24, 2272-6	7	76
71	Recent developments in multiple system atrophy. *Journal of Neurology*, **2009**, 256, 1791-808	5.5	81
70	Striatal transplantation for multiple system atrophy--are grafts affected by alpha-synucleinopathy?. *Experimental Neurology*, **2009**, 219, 368-71	5.7	27
69	No need to droop your head in Parkinson's disease?. *Parkinsonism and Related Disorders*, **2009**, 15, 620	3.6	
68	Prospective differentiation of multiple system atrophy from Parkinson disease, with and without autonomic failure. *Archives of Neurology*, **2009**, 66, 742-50		113
67	Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. *Experimental Neurology*, **2008**, 210, 421-7	5.7	68

66	Parkinson-Plus Disorders **2008**, 157-175		1
65	Survival in multiple system atrophy. *Movement Disorders*, **2008**, 23, 294-6	7	91
64	Red flags for multiple system atrophy. *Movement Disorders*, **2008**, 23, 1093-9	7	168
63	Multiple system atrophy: a primary oligodendrogliopathy. *Annals of Neurology*, **2008**, 64, 239-46	9.4	239
62	Loss of dopaminergic responsiveness in a double lesion rat model of the Parkinson variant of multiple system atrophy. *Movement Disorders*, **2007**, 22, 353-8	7	13
61	Safety and tolerability of growth hormone therapy in multiple system atrophy: a double-blind, placebo-controlled study. *Movement Disorders*, **2007**, 22, 1138-44	7	55
60	Diffusion weighted imaging best discriminates PD from MSA-P: A comparison with tilt table testing and heart MIBG scintigraphy. *Movement Disorders*, **2007**, 22, 1771-6	7	73
59	Disproportionate antecollis: a warning sign for multiple system atrophy. *Movement Disorders*, **2007**, 22, 1986; author reply 1986-7	7	5
58	Microglial activation mediates neurodegeneration related to oligodendroglial alpha-synucleinopathy: implications for multiple system atrophy. *Movement Disorders*, **2007**, 22, 2196-203	7	179
57	Progression of brain atrophy in multiple system atrophy. A longitudinal VBM study. *Journal of Neurology*, **2007**, 254, 191-6	5.5	100
56	The diagnosis of Parkinson's disease. *Lancet Neurology, The*, **2006**, 5, 75-86	24.1	476
55	Cortical atrophy in the cerebellar variant of multiple system atrophy: a voxel-based morphometry study. *Movement Disorders*, **2006**, 21, 159-65	7	61
54	Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG). *Movement Disorders*, **2006**, 21, 179-86	7	114
53	Health-related quality of life in multiple system atrophy. *Movement Disorders*, **2006**, 21, 809-15	7	83
52	Topography of putaminal degeneration in multiple system atrophy: a diffusion magnetic resonance study. *Movement Disorders*, **2006**, 21, 847-52	7	55
51	Olivopontocerebellar atrophy: toward a better nosological definition. *Movement Disorders*, **2006**, 21, 1607-13	7	45
50	Progression of putaminal degeneration in multiple system atrophy: a serial diffusion MR study. *NeuroImage*, **2006**, 31, 240-5	7.9	84
49	The diagnosis of multiple system atrophy. *Journal of Neurology*, **2006**, 253, iii2-iii15	5.5	3

48	Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy. *American Journal of Pathology*, **2005**, 166, 869-76	5.8	173
47	Placebo-controlled trial of amantadine in multiple-system atrophy. *Clinical Neuropharmacology*, **2005**, 28, 225-7	1.4	34
46	Animal models of multiple system atrophy. *Trends in Neurosciences*, **2005**, 28, 501-6	13.3	71
45	How to diagnose dementia with Lewy bodies: state of the art. *Movement Disorders*, **2005**, 20 Suppl 12, S11-20	7	255
44	Grading of neuropathology in multiple system atrophy: proposal for a novel scale. *Movement Disorders*, **2005**, 20 Suppl 12, S29-36	7	132
43	In vitro models of multiple system atrophy. *Movement Disorders*, **2005**, 20 Suppl 12, S53-6	7	19
42	Therapeutic strategies in multiple system atrophy. *Movement Disorders*, **2005**, 20 Suppl 12, S67-76	7	32
41	The role of alpha-synuclein in the pathogenesis of multiple system atrophy. *Acta Neuropathologica*, **2005**, 109, 129-40	14.3	87
40	Progression of parkinsonism in multiple system atrophy. *Journal of Neurology*, **2005**, 252, 91-6	5.5	47
39	Multiple system atrophy **2005**, 623-662		2
38	Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. *Brain*, **2005**, 128, 1605-12	11.2	102
37	Multiple system atrophy. *Lancet Neurology, The*, **2004**, 3, 93-103	24.1	377
36	Failure of neuronal protection by inhibition of glial activation in a rat model of striatonigral degeneration. *Journal of Neuroscience Research*, **2004**, 78, 87-91	4.4	26
35	Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. *Movement Disorders*, **2004**, 19, 1020-8	7	1259
34	Comparison of diffusion-weighted imaging and [123I]IBZM-SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease. *Movement Disorders*, **2004**, 19, 1438-45	7	78
33	Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). *Movement Disorders*, **2004**, 19, 1391-402	7	372
32	Trace of diffusion tensor differentiates the Parkinson variant of multiple system atrophy and Parkinson's disease. *NeuroImage*, **2004**, 21, 1443-51	7.9	127
31	Basal forebrain atrophy is a distinctive pattern in dementia with Lewy bodies. *NeuroReport*, **2004**, 15, 1711-4	1.7	35

30	Neuropathological and behavioral changes induced by various treatment paradigms with MPTP and 3-nitropropionic acid in mice: towards a model of striatonigral degeneration (multiple system atrophy). *Acta Neuropathologica*, **2003**, 106, 157-66	14.3	46
29	Tumor necrosis factor-alpha-induced cell death in U373 cells overexpressing alpha-synuclein. *Journal of Neuroscience Research*, **2003**, 73, 334-40	4.4	33
28	Increased daytime sleepiness in Parkinson's disease: a questionnaire survey. *Movement Disorders*, **2003**, 18, 319-323	7	57
27	Voxel-based morphometry detects cortical atrophy in the Parkinson variant of multiple system atrophy. *Movement Disorders*, **2003**, 18, 1132-8	7	135
26	Multiple system atrophy: an update. *Movement Disorders*, **2003**, 18 Suppl 6, S34-42	7	58
25	Freezing of gait in postmortem-confirmed atypical parkinsonism. *Movement Disorders*, **2002**, 17, 1041-5	7	39
24	Is peripheral neuropathy a feature of multiple system atrophy?. *Clinical Autonomic Research*, **2001**, 11, 63	4.3	1
23	Glial cell death induced by overexpression of alpha-synuclein. *Journal of Neuroscience Research*, **2001**, 65, 432-8	4.4	77
22	Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders. *Archives of Neurology*, **2001**, 58, 259-64		291
21	Simultaneous intrastriatal 6-hydroxydopamine and quinolinic acid injection: a model of early-stage striatonigral degeneration. *Experimental Neurology*, **2001**, 167, 133-47	5.7	47
20	An early report of striatonigral degeneration. *Movement Disorders*, **2000**, 15, 159-62	7	6
19	Cortical and brain stem hyperexcitability in a pathologically confirmed case of multiple system atrophy. *Movement Disorders*, **2000**, 15, 362-3	7	16
18	Toward a primate model of L-dopa-unresponsive parkinsonism mimicking striatonigral degeneration. *Movement Disorders*, **2000**, 15, 531-6	7	36
17	Impaired dopaminergic neurotransmission in patients with traumatic brain injury: a SPECT study using 123I-beta-CIT and 123I-IBZM. *European Journal of Nuclear Medicine and Molecular Imaging*, **2000**, 27, 1410-4		109
16	Failure of neuroprotection by embryonic striatal grafts in a double lesion rat model of striatonigral degeneration (multiple system atrophy). *Experimental Neurology*, **2000**, 164, 166-75	5.7	14
15	Progression of falls in postmortem-confirmed parkinsonian disorders. *Movement Disorders*, **1999**, 14, 947-50	7	122
14	The tau gene in progressive supranuclear palsy: exclusion of mutations in coding exons and exon 10 splice sites, and identification of a new intronic variant of the disease-associated H1 haplotype in Italian cases. *Neuroscience Letters*, **1999**, 274, 61-5	3.3	24
13	123I-beta-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease. *Movement Disorders*, **1998**, 13, 438-45	7	39

12	Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology. *Clinical Autonomic Research*, **1998**, 8, 359-62	4.3	248
11	Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. *European Journal of Nuclear Medicine and Molecular Imaging*, **1997**, 24, 320-5		123
10	The "cold hands sign" in multiple system atrophy. *Movement Disorders*, **1997**, 12, 514-8	7	46
9	Magnetic resonance imaging of multiple system atrophy167-203		
8	Corticobasal degeneration75-98		1
7	Multiple system atrophy1-15		
6	Parkinsonism □other causes99-125		
5	The differential diagnosis of parkinsonism: A clinical approach126-141		
4	Parkinson□s disease and the spectrum of Lewy body disease10-26		
3	Multiple system atrophy27-57		
2	Progressive supranuclear palsy58-74		
1	Non-pharmacological treatment for atypical parkinsonism142-159		